The relationship between adipokines and the onset of type 2 diabetes in middle-aged men: The PRIME study
Standard
The relationship between adipokines and the onset of type 2 diabetes in middle-aged men: The PRIME study. / Neville, Charlotte E; Patterson, Christopher C; Linden, Gerard J; Love, Karl; McKinley, Michelle C; Kee, Frank; Blankenberg, Stefan; Evans, Alun; Yarnell, John; Woodside, Jayne V.
in: DIABETES RES CLIN PR, Jahrgang 120, 10.2016, S. 24-30.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The relationship between adipokines and the onset of type 2 diabetes in middle-aged men: The PRIME study
AU - Neville, Charlotte E
AU - Patterson, Christopher C
AU - Linden, Gerard J
AU - Love, Karl
AU - McKinley, Michelle C
AU - Kee, Frank
AU - Blankenberg, Stefan
AU - Evans, Alun
AU - Yarnell, John
AU - Woodside, Jayne V
N1 - Crown Copyright © 2016. Published by Elsevier Ireland Ltd. All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - AIMS: Epidemiological evidence suggests that adipokines may be associated with the onset of type 2 diabetes, but the evidence to date is limited and inconclusive. This study examined the association between adiponectin and leptin and the subsequent diagnosis of type 2 diabetes in a UK population based cohort of non-diabetic middle-aged men.METHODS: Baseline serum levels of leptin and adiponectin were measured in 1839 non-diabetic men aged 50-60years who were participating in the prospective population-based PRIME study. Over a mean follow-up of 14.7years, new cases of type 2 diabetes were determined from self-reported clinical information with subsequent validation by general practitioners.RESULTS: 151 Participants developed type 2 diabetes during follow-up. In Cox regression models adjusted for age, men in the top third of the leptin distribution were at increased risk (hazard ratio (HR) 4.27, 95% CI 2.67-6.83) and men in the top third of the adiponectin distribution at reduced risk (HR 0.24, 95% CI 0.14-0.42) relative to men in the bottom third. However, significance was lost for leptin after additional adjustment for BMI, waist to hip ratio, lifestyle factors and biological risk factors, including C-reactive protein (CRP). Further adjustment for HOMA-IR also resulted in loss of significance for adiponectin.CONCLUSIONS: This study provides evidence that adipokines are associated with men's future type 2 diabetes risk but not independently of other risk factors.
AB - AIMS: Epidemiological evidence suggests that adipokines may be associated with the onset of type 2 diabetes, but the evidence to date is limited and inconclusive. This study examined the association between adiponectin and leptin and the subsequent diagnosis of type 2 diabetes in a UK population based cohort of non-diabetic middle-aged men.METHODS: Baseline serum levels of leptin and adiponectin were measured in 1839 non-diabetic men aged 50-60years who were participating in the prospective population-based PRIME study. Over a mean follow-up of 14.7years, new cases of type 2 diabetes were determined from self-reported clinical information with subsequent validation by general practitioners.RESULTS: 151 Participants developed type 2 diabetes during follow-up. In Cox regression models adjusted for age, men in the top third of the leptin distribution were at increased risk (hazard ratio (HR) 4.27, 95% CI 2.67-6.83) and men in the top third of the adiponectin distribution at reduced risk (HR 0.24, 95% CI 0.14-0.42) relative to men in the bottom third. However, significance was lost for leptin after additional adjustment for BMI, waist to hip ratio, lifestyle factors and biological risk factors, including C-reactive protein (CRP). Further adjustment for HOMA-IR also resulted in loss of significance for adiponectin.CONCLUSIONS: This study provides evidence that adipokines are associated with men's future type 2 diabetes risk but not independently of other risk factors.
KW - Adiponectin/blood
KW - Biomarkers/blood
KW - C-Reactive Protein/metabolism
KW - Diabetes Mellitus, Type 2/blood
KW - Humans
KW - Incidence
KW - Leptin/blood
KW - Male
KW - Middle Aged
KW - Proportional Hazards Models
KW - Prospective Studies
KW - Risk Factors
KW - United Kingdom/epidemiology
U2 - 10.1016/j.diabres.2016.07.010
DO - 10.1016/j.diabres.2016.07.010
M3 - SCORING: Journal article
C2 - 27500548
VL - 120
SP - 24
EP - 30
JO - DIABETES RES CLIN PR
JF - DIABETES RES CLIN PR
SN - 0168-8227
ER -